ASCO presentation: Six-month, follow-up data from the pivotal phase III study of ponatinib in chronic myelogenous leukemia.What we already know: Results from the first three months of the ponatinib PACE study were presented last December. Key questions: Investors will be looking for six-month response rates to be higher than what was seen last December.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts